On Thursday Eastern Time, the US Food and Drug Administration (FDA) announced that the best-selling weight loss drug Zepbound from Eli Lilly is no longer in short supply, which will have a serious impact on the multi billion dollar compound medicine market. After the news was released, American telemedicine company Hims& Hers Health's stock price plummeted by over 10%.